Ben Harrison
Overview
Explore the profile of Ben Harrison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harrison B, Raju D, Garmory H, Brett M, Titball R, Sarker M
Appl Environ Microbiol
. 2024 Apr;
90(5):e0025924.
PMID: 38606962
No abstract available.
2.
Schwartz O, Amminger P, Baune B, Bedi G, Berk M, Cotton S, et al.
Trials
. 2023 Oct;
24(1):686.
PMID: 37875938
Background: Existing treatments for young people with severe depression have limited effectiveness. The aim of the Study of Ketamine for Youth Depression (SKY-D) trial is to determine whether a 4-week...
3.
Thomas S, Wattenberg M, Choi-Bose S, Uhlik M, Harrison B, Coho H, et al.
Nat Commun
. 2023 Oct;
14(1):6330.
PMID: 37816712
Although macrophages contribute to cancer cell dissemination, immune evasion, and metastatic outgrowth, they have also been reported to coordinate tumor-specific immune responses. We therefore hypothesized that macrophage polarization could be...
4.
Harrison B, Bond R
Vascular
. 2023 May;
32(5):957-963.
PMID: 37249070
Objectives: To demonstrate the ease with which steerable sheaths, designed for cardiac electrophysiological applications, can be used to aid endovascular treatment of a wide range of non-cardiac vascular disease and...
5.
Wang H, Zhou D, Luk S, In Cha H, Mac A, Chae R, et al.
Neurobiol Dis
. 2022 Dec;
176:105944.
PMID: 36493974
Many patients with autism spectrum disorders (ASD) show disturbances in their sleep/wake cycles, and they may be particularly vulnerable to the impact of circadian disruptors. We have previously shown that...
6.
Ney L, Laing P, Steward T, Zuj D, Dymond S, Harrison B, et al.
PLoS One
. 2022 May;
17(5):e0268814.
PMID: 35609058
Fear conditioning paradigms are critical to understanding anxiety-related disorders, but studies use an inconsistent array of methods to quantify the same underlying learning process. We previously demonstrated that selection of...
7.
BDNF genotype Val66Met interacts with acute plasma BDNF levels to predict fear extinction and recall
Ney L, Matthews A, Nicholson E, Zuj D, Ken Hsu C, Steward T, et al.
Behav Res Ther
. 2021 Aug;
145:103942.
PMID: 34340176
Brain-derived neurotropic factor (BDNF) is a potent regulator of memory processes and is believed to influence the consolidation of fear extinction memories. No previous human study has tested the effect...
8.
Ney L, Matthews A, Hsu C, Zuj D, Nicholson E, Steward T, et al.
Depress Anxiety
. 2021 Jun;
38(10):1087-1099.
PMID: 34151472
Background: The endocannabinoid system is gaining increasing attention as a favorable target for improving posttraumatic stress disorder (PTSD) treatments. Exposure therapy is the gold-standard treatment for PTSD, and fear extinction...
9.
Hurley P, Bose N, Jha G, Gargano M, Ottoson N, Gorden K, et al.
Anticancer Res
. 2020 Mar;
40(3):1467-1473.
PMID: 32132045
Background: BTH1677 is a beta-glucan pathogen-associated molecular pattern (PAMP) being evaluated as a novel immunotherapy of cancer. We previously described that the presence of antibodies against beta-glucan (ABA) in serum...
10.
Bose N, Ottoson N, Qiu X, Harrison B, Lowe J, Uhlik M, et al.
J Immunol
. 2019 Apr;
202(10):2945-2956.
PMID: 30988115
Imprime PGG (Imprime) is an i.v. administered, yeast β-1,3/1,6 glucan in clinical development with checkpoint inhibitors. Imprime-mediated innate immune activation requires immune complex formation with naturally occurring IgG anti-β glucan...